ImmVira announced that it has initiated its lead oncolytic virus therapy program MVR-T3011 IV (also known as T3011). The first patient has been dosed, receiving MVR-T3011 intravenous (IV) administration in the U.S. on August 10, 2021.
European regulators have expanded the treatment scope of Amgen’s Xgeva to include the prevention of skeletal-related events in adults with multiple myeloma.